Efficacy and safety of intravenous calcium supplementation on migraine and osteoporosis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300067779

Enrollment

Unknown

Registered

2023-01-23

Start date

2023-05-04

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine and osteoporosis

Interventions

Treatment group:intravenous calcium

Control group:normal saline

Eligibility

Sex/Gender

All

Age

16 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for migraine and osteoporosis; 2. Agree to participate in this study; 3. Have not taken any hormone drugs and other drugs that affect the study for at least 3 months before enrollment; 4. Basic The disease is stable and does not affect treatment and observation; 5. Approved by the hospital ethics committee.

Exclusion criteria

Exclusion criteria: 1. Intellectual, mental, cognitive dysfunction or other nervous system dysfunction; 2. Taking drugs that affect treatment and observation; 3. Severe underlying diseases; 4. Patients with hypercalcemia; 5. Heart disease decline.

Design outcomes

Primary

Measure	Time frame
the mean change in the average number of headache days;bone density;Fracture incidence;	—

Countries

China

Contacts

Public ContactShengkai Ye

The 967th Hospital of P.L.A

yeshengkai@163.com+86 134 7876 7269

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026